ANI Pharmaceuticals, Inc. (ANIP)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 67.11 |
| Open | 67.87 |
| Bid | 67.01 x 100 |
| Ask | 67.46 x 100 |
| Day's range | 66.65 - 67.87 |
| 52-week range | 37.87 - 70.81 |
| Volume | |
| Avg. volume | 145,387 |
| Market cap | 1.411B |
| Beta (5Y monthly) | 0.80 |
| PE ratio (TTM) | 79.12 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
Agios (AGIO) Q1 Earnings Surpass, Sales Miss Estimates
Agios (AGIO) reports mixed earnings results for first-quarter 2024. Though sales miss the mark, revenues from its sole marketed drug, Pyrukynd, rise sequentially and on a yearly basis.
- Zacks
ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
ANI (ANIP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Blueprint (BPMC) Q1 Earnings and Revenues Beat, Stock Rises
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
© 2024 Yahoo. All rights reserved.